Fate Of FOB Legislation Under New Congress Is Front And Center At BIO CEO Conference
This article was originally published in The Pink Sheet Daily
Executive Summary
BIO may be back to the drawing board in its lobbying push for lengthy exclusivity periods in follow-on biologics legislation, policy experts say.